🌟 Congratulations to Panacea Biotec, a valued member of DCVMN, for their strides in advancing vaccine equity! Their recent launch of EasyFourPol in India and the successful registration of Valganciclovir Powder for Oral Solution in Germany exemplifies their commitment to global healthcare.
EasyFourPol stands out as the world’s first fully liquid wP-IPV Pentavalent vaccine, protecting children against five severe diseases: Diphtheria, Tetanus, Pertussis, Polio, and invasive infections caused by Haemophilus Influenza Type b. This ready-to-use combination vaccine matches the protection level of single-antigen vaccines, minimizing clinic visits, and cutting overall immunization costs for all involved. By reducing vaccinations and shots for children, it ensures greater comfort for parents and better compliance for healthcare providers. Moreover, fewer shots mean the reduction carbon emissions by lessening the demand for vials, syringes, packaging materials, and visits to vaccine centers!
DCVMN is proud to have members like Panacea Biotec, whose dedication contributes to the worldwide fight for accessible, innovative and sustainable healthcare solutions!
Read more about this: https://www.panaceabiotec.com/en/content/panacea-biotec-launches-easyfourpol-in-india-and-receives-registration-of-valganciclovir-powder-for-oral-solution-in-germany
